MiniMed Group (MMED), the diabetes business subsidiary of Medtronic (MDT), priced its initial public offering of 28M shares of its common stock at $20.00, below the target range of $25.00-$28.00. Goldman Sachs, BofA, Citi and Morgan Stanley are acting as joint book running managers for the offering.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MMED: